Oncology Institute (TOI) Income towards Parent Company (2020 - 2026)

Oncology Institute (TOI) has reported Income towards Parent Company for 7 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$2.5 million, up 87.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$43.5 million (up 32.39% YoY), and the FY2025 annual result was -$60.6 million, up 6.27% from the prior year.
• Income towards Parent Company was -$2.5 million for Q1 2026 at Oncology Institute, up from -$7.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $19.3 million in Q1 2022 and troughed at -$30.0 million in Q1 2023.
• Average Income towards Parent Company over 5 years is -$12.4 million, with a median of -$16.1 million recorded in 2024.
• Year-over-year, Income towards Parent Company surged 2036.35% in 2022 and plunged 551.42% in 2023.
• Over 5 years, Income towards Parent Company stood at -$11.0 million in 2022, then tumbled by 70.38% to -$18.8 million in 2023, then advanced by 29.71% to -$13.2 million in 2024, then jumped by 43.04% to -$7.5 million in 2025, then soared by 66.81% to -$2.5 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$2.5 million in Q1 2026, -$7.5 million in Q4 2025, and -$16.5 million in Q3 2025.